Entera Bio GAAP EPS of -$0.06 beats by $0.10

1 hour ago 1

Entera Bio press release (NASDAQ:ENTX): Q2 GAAP EPS of -$0.06 beats by $0.10.
Cash and cash equivalents were $18.9 million as of June 30, 2025, including $8.0 million in restricted cash designated to fund the OPKO collaboration through Phase 1 studies of oral GLP-1/glucagon candidate OPK-88006.
Cash on hand is expected to support operations through mid-third quarter 2026.

Recommended For You